Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension (OSCAR)

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3

Conditions

Essential Hypertension

Treatments

Drug: olmesartan alone or in combination with hydrochlorothiazide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00139698
A0021002

Details and patient eligibility

About

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject has mild to moderate hypertension

Exclusion criteria

  • History of secondary hypertension

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

32

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems